Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1/2017

Open Access 01-02-2017 | Environment and Autoimmunity

Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature

Authors: Beniamino Palmieri, Dimitri Poddighe, Maria Vadalà, Carmen Laurino, Carla Carnovale, Emilio Clementi

Published in: Immunologic Research | Issue 1/2017

Login to get access

Abstract

Human papilloma virus (HPV) is recognized as a major cause for cervical cancer among women worldwide. Two HPV vaccines are currently available: Gardasil® and Cervarix®. Both vaccines enclose viral antigenic proteins, but differ as to the biological systems of culture and the adjuvant components. Recently, a collection of symptoms, indicating nervous system dysfunction, has been described after HPV vaccination. We retrospectively described a case series including 18 girls (aged 12–24 years) referred to our “Second Opinion Medical Network” for the evaluation of “neuropathy with autonomic dysfunction” after HPV vaccination. All girls complained of long-lasting and invalidating somatoform symptoms (including asthenia, headache, cognitive dysfunctions, myalgia, sinus tachycardia and skin rashes) that have developed 1–5 days (n = 11), 5–15 days (n = 5) and 15–20 days (n = 2) after the vaccination. These cases can be included in the recently described immune dysfunction named autoimmune/inflammatory syndrome induced by adjuvants (ASIA). HPV vaccine, through its adjuvant component, is speculated to induce an abnormal activation of the immune system, involving glia cells in the nervous system too. Further researches should aim at defining the pathological and clinical aspects of these post-vaccination diseases and identifying a genetic background predisposing to these adverse reactions.
Literature
1.
Shiller JT, Lowy DR. Virus infections and human cancer: an overview. Recent Results Cancer Res. 2014;193:1–10.CrossRef
2.
Malik H, Khan FH, Ahsan H. Human papillomavirus: current status and issues of vaccination. Arch Virol. 2014;159:199–205.CrossRefPubMed
3.
Schiller JT, Lowy DR, Markowitz LE. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders; 2013. p. 235–56.
4.
O’Hagan DT. Preparation methods and research protocols. In: Vaccine adjuvants. Humana Press; 2000. p. 1–342.
5.
Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine. 2007;25(16):3001–6.CrossRefPubMed
6.
Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.CrossRefPubMedPubMedCentral
7.
Nicol AF, de Andrade CV, Russomano FB, Rodrigues LS, Oliveira NS, Provance DW Jr, Nuovo GJ. HPV vaccines: their pathology-based discovery, benefits, and adverse effects. Ann Diagn Pathol. 2015;19(6):418–22.CrossRefPubMed
8.
Stratton K, Ford A, Rusch E, Clayton EW. Adverse effects of vaccines, evidence and causality. The National Academies Press; 2012. p. 1–866.
9.
Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32(9):1302–7.CrossRef
10.
Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine. 2015;33(13):1608–13.CrossRefPubMed
11.
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161–70.CrossRefPubMed
12.
Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702.CrossRefPubMed
13.
Centers for Disease Control and Prevention. (CDC) National and state vaccination coverage among adolescents aged 13–17 years–United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(34):685–93.
14.
Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645–51.CrossRefPubMed
15.
Hutchinson DJ, Klein KC. Human papillomavirus disease and vaccines. Am J Health Syst Pharm. 2008;65:2105–12.CrossRefPubMed
16.
Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–4.PubMed
17.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.CrossRefPubMed
18.
McCormack PL. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. Drugs. 2014;74(11):1253–83.CrossRefPubMed
19.
Pellegrino P, Falvella FS, Perrone V, Carnovale C, Brusadelli T, Pozzi M, et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J. 2015;15(3):284–7.CrossRefPubMed
20.
Pellegrino P, Carnovale C, Pozzi M, Antoniazzi S, Perrone V, Salvati D, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev. 2014;13(7):736–41.CrossRefPubMed
21.
Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: current evidence and future perspectives. Autoimmun Rev. 2015;14(10):880–8.CrossRefPubMed
22.
Shoenfeld Y, Agmon-Levin N. ASIA—Autoimmune/inflammatory syndrome induced by adjuvants. J Autoimm. 2011;36:4–8.CrossRef
23.
Poddighe D, Castelli L, Marseglia GL, Bruni P. A sudden onset of a pseudo-neurological syndrome after HPV-16/18 AS04-adjuvated vaccine: might it be an autoimmune/inflammatory syndrome induced by adjuvants (ASIA) presenting as a somatoform disorder? Immunol Res. 2014;60(2–3):236–46.CrossRefPubMed
24.
Stubgen JP. A review on the association between inflammatory myopathies and vaccination. Autoimmun Rev. 2014;13(1):31–9.CrossRefPubMed
25.
Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014;13(3):215–24.CrossRefPubMed
26.
Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders; 2013. p. 1–13.
27.
28.
Van der Laan JW, Gould S, Tanir JY. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine. 2015;33(13):1507–14.CrossRefPubMed
29.
Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence. Lancet. 2003;362:1659–66.CrossRefPubMed
30.
Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408.CrossRefPubMed
31.
Offit PA, De Stefano F. Vaccine safety. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders; 2013. p. 1464–80.
32.
Rajantie J, Zeller B, Treutiger I, Rosthöj S. Vaccination associated thrombocytopenic purpura in children. Vaccine. 2007;25:1838–40.CrossRefPubMed
33.
34.
Guimarães LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190–209.CrossRefPubMed
35.
Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res. 2015;92:8–22.CrossRef
36.
37.
Kuroda E, Coban C, Ishii KJ. Particulate adjuvants and innate immunity: past achievements, present findings and future prospects. Int Rev Immunol. 2013;32:209–20.CrossRefPubMedPubMedCentral
38.
Mohan T, Verma P, Rao DN. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res. 2013;138(5):779–95.PubMedPubMedCentral
39.
Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) 2013: unveiling the pathogenic, clinical and diagnostic aspects. J Autoimm. 2013;47:1–16.CrossRef
40.
Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (auto-inflammatory) Syndrome Induced by Adjuvants (ASIA)—Animal models as proof of concept. Curr Med Chem. 2013;20(32):4030–6.CrossRefPubMed
41.
Shoenfeld Y. Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld. BMC Med. 2013;11:118.
42.
Zafrir Y, Agmon-Levin N, Shilton T, Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of Autoimmune(Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA): analysis of 93 cases. Lupus. 2012;21:146–52.CrossRefPubMed
43.
Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E, Radice S. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015;61(1–2):90–6.CrossRefPubMed
44.
Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31:4961–7.CrossRefPubMed
45.
46.
Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol. 2014;21:135–9.CrossRefPubMed
47.
Martinez-Lavin M. Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination. J Clin Rheumatol. 2014;20:392–3.CrossRefPubMed
48.
Martínez-Lavín M. Hypothesis: Human papillomavirus vaccination syndrome—small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol. 2015;34:1165–9.CrossRefPubMed
49.
Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53:2185–200.CrossRefPubMed
50.
Brinth L, Theibel AC, Pors K, Mehlsen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J. 2015;62(4):A5064.PubMed
51.
Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015;34:1981–3.CrossRefPubMed
52.
List des effects indesirables suite a la vaccination HPV en France. Confidential document received by the corresponding author.
53.
Asociacion de afectadas por la vacuna del papiloma (AAVP). Spanish AAVP database of HPV vaccine affected girls. Confidential document received by the corresponding author.
54.
Association of HPV Vaccine Injured Daughters (AHVID). Database of HPV vaccine affected girls. Confidential document received by the corresponding author.
55.
56.
57.
58.
Mitchell LA, et al. HLA-DR class II associations with rubella vaccine-induced joint manifestations. J Infect Dis. 1998;177(1):5–12.CrossRefPubMed
59.
Ahmed SS, Schur PH, MacDonald NE, Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun. 2014;50:1–11.CrossRefPubMed
60.
Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13(6):600–13.CrossRefPubMed
61.
Faust H, Toft L, Sehr P, Müller M, Bonde J, Forslund O, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–65.CrossRefPubMed
62.
Göppert TM, Müller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target. 2005;13(3):179–87.CrossRefPubMed
63.
Metadata
Title
Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature
Authors
Beniamino Palmieri
Dimitri Poddighe
Maria Vadalà
Carmen Laurino
Carla Carnovale
Emilio Clementi
Publication date
01-02-2017
Publisher
Springer US
Published in
Immunologic Research / Issue 1/2017
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8820-z

Other articles of this Issue 1/2017

Immunologic Research 1/2017 Go to the issue

Environment and Autoimmunity

Autoimmune reaction after anti-tetanus vaccination—description of four cases and review of the literature

Mechanism in Autoimmunity

New automated indirect immunofluorescent antinuclear antibody testing compares well with established manual immunofluorescent screening and titration for antinuclear antibody on HEp-2 cells

Mechanism in Autoimmunity

Primary Sjögren’s syndrome: clinical phenotypes, outcome and the development of biomarkers

Mechanism in Autoimmunity

Irregular antibodies in no hemolytic autoimmune diseases are able to induce erythrophagocytosis

Environment and Autoimmunity

Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil

Mechanism in Autoimmunity

Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study